Key result
Overexpression of miR-125b enhanced doxorubicin-induced cardiotoxicity in vitro and in vivo by targeting the STARD13/YAP axis, whereas its inhibition exhibited a protective effect.
Why the study?
The clinical use of doxorubicin is limited by cardiotoxicity with incompletely understood pathogenesis, prompting investigation into the role of miR-125b.
Does miR-125b modulation affect doxorubicin-induced cardiotoxicity in preclinical models?
Does miR-125b modulation affect doxorubicin-induced cardiotoxicity in preclinical models?
miR-125b enhances doxorubicin-induced cardiotoxicity by targeting the STARD13/YAP axis, suggesting a potential therapeutic target for preventing doxorubicin-induced heart damage.
miR-125b modulation may influence Dox cardiotoxicity in models; leaves open human relevance and therapeutic targeting.
The clinical application of doxorubicin (Dox) is limited due to its cardiotoxicity, while the pathogenesis remains to be fully understood. Recent studies have suggested that microRNA (miRNA) plays an important role in Dox-induced cardiotoxicity. This work aims to investigate the effects of miR-125b in Dox-induced cardiotoxicity. Here, mice model combined with cell line analysis were used, and cell viability assay, detection of reactive oxygen species (ROS), malondialdehyde (MDA) activity, lactate dehydrogenase (LDH) activity, glutathione (GSH) level, glutathione peroxidase (GSH-Px) level, superoxide dismutase (SOD) activity, and histopathological changes were performed to characterize miR-125b effects; real-time quantitative polymerase chain reaction (PCR), luciferase reporter assay, RNA immunoprecipitation, and western blot analysis were subjected to reveal the underlying mechanisms. It was found that miR-125b level was upregulated in myocardial cell line H9C2 treated with Dox and miR-125b overexpression enhanced Dox-induced cytotoxicology of H9C2 cells, while miR-125b inhibition exhibited a protective effect by measuring ROS level and cell viability. In consistent, in vivo experiments with miR-125b agomir or antagomir obtained a consistent result through examining the activity of MDA, LDH, GSH, GSH-Px, SOD, and histopathological changes. Furthermore, we found that miR-125b could target STARD13 and thus suppressed the nucleus-cytoplasmic translocation of yes-associated protein (YAP). Additionally, this STARD13/YAP axis is necessary for miR-125b-mediated regulation on Dox-induced cytotoxicology of H9C2 cells. In conclusion, our study demonstrated that miR-125b could enhance Dox-induced cardiotoxicity through targeting the STARD13/YAP axis.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2021) studied Doxorubicin-induced cardiotoxicity. miR-125b modulation vs. Control was evaluated on Cardiotoxicity (cell viability, ROS, MDA, LDH, GSH, GSH-Px, SOD, histopathological changes). Overexpression of miR-125b enhanced doxorubicin-induced cardiotoxicity in vitro and in vivo by targeting the STARD13/YAP axis, whereas its inhibition exhibited a protective effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: